Brief: Eisai Submits Marketing Authorisation Variation To EMA For Intravenous Maintenance Dosing With Leqembi
26/01/2026 21:03
Jan 26 (Reuters) - Bioarctic Ab BIOAb.ST: EISAI SUBMITS MARKETING AUTHORISATION VARIATION TO EMA FOR INTRAVENOUS MAINTENANCE DOSING EVERY FOUR WEEKS WITH LEQEMBI® (LECANEMAB) Source text: ID:nWkr9RC9Z8 Further company coverage: BIOAb.ST ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln